Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KIN-INFL
- Development stage
- Preclinical
- Lead developer
- Kintsugi Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KIN-INFL is a preclinical-stage small molecule Caspase-1 inhibitor being developed by Kintsugi Therapeutics for the treatment of inflammasome-driven diseases, including autoinflammatory diseases, inflammatory bowel disease, and idiopathic pulmonary fibrosis. As a peptide-derived inhibitor, KIN-INFL interacts with Caspase-1 via a reactive warhead to inhibit its protease activity. This inhibition blocks the processing and secretion of pro-inflammatory cytokines interleukin-1 beta (IL-1beta) and interleukin-18 (IL-18), as well as the induction of pyroptosis, a form of lytic cell death. The therapeutic candidate is currently in preclinical development.
02
Targets
CASP1 (Caspase-1)
Beyond the preview
Go deeper on KIN-INFL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KIN-INFL.